Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice by Cain, H. et al.
lable at ScienceDirect
Clinical Oncology 29 (2017) 642e652Contents lists avaiClinical Oncology
journal homepage: www.cl in icaloncologyonl ine.netOverviewNeoadjuvant Therapy in Early Breast Cancer: Treatment
Considerations and Common Debates in Practice
H. Cain *1, I.R. Macpherson y1, M. Beresford z, S.E. Pinder x, J. Pong{, J.M. Dixon jj
*Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
yDepartment of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
zDepartment of Clinical Oncology, The Royal United Hospital, Bath, UK
xDivision of Cancer Studies, King’s College London, Guy’s Hospital, London, UK
{Roche Products Ltd, Welwyn Garden City, UK
jj Edinburgh Breast Unit, Western General Hospital, NHS Lothian, Edinburgh, UKReceived 2 January 2017; received in revised form 11 May 2017; accepted 17 May 2017
Abstract
Neoadjuvant treatment offers a number of benefits for patients with early breast cancer, and is an important option for consideration by multidisciplinary
teams. Despite literature showing its efficacy, the use of neoadjuvant therapy varies widely. Here we discuss the clinical evidence supporting the use of
neoadjuvant therapy in early stage breast cancer, including patient selection, monitoring response, surgery and radiotherapy considerations, with the aim of
assisting multidisciplinary teams to determine patient suitability for neoadjuvant treatment.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Originally a means to downstage patients with inoper-
able locally advanced breast cancer, neoadjuvant therapy is
now integral to the treatment of patients with early stage
disease. Large clinical trials such as EORTC 10902 and
NSABP B-18 have shown no differences between the same
systemic therapy given pre- or post-surgery on disease-free
(DFS) and overall survival [1e3]. Other benefits (i.e. the
conversion of patients requiring mastectomy to breast-
conserving surgery [BCS]) and some potential concerns
have been investigated and are well recognised (Table 1). It
is therefore important for the multidisciplinary team (MDT)
to consider the benefits and risks when selecting patients
who may benefit from neoadjuvant therapy.Author for correspondence: H. Cain, Royal Victoria Infirmary, Queen
Victoria Road, Newcastle upon Tyne NE1 4LP, UK. Tel: þ44-191-28-26192.
E-mail address: henry.cain@nuth.nhs.uk (H. Cain).
1 Equal contributions as lead authors.
http://dx.doi.org/10.1016/j.clon.2017.06.003
0936-6555/ 2017 The Royal College of Radiologists. Published by Elsevier Lt
creativecommons.org/licenses/by-nc-nd/4.0/).Anthracycline plus taxane-based chemotherapy is the
mostwidelyusedneoadjuvant chemotherapy (NAC) regimen
for all early breast cancer subtypes and is associated with
high rates of clinical response (up to 90% inNSABPB-27) [15].
Progression duringNAC is infrequent, with a rate of 3% in one
meta-analysis of 1928 patients [16]. In patients with human
epidermal growth factor receptor 2 (HER2)-positive breast
cancer, trastuzumab with or without pertuzumab should be
administered concomitantly with a taxane [17e19]. For pa-
tientswith triple negative breast cancer (TNBC), the addition
of carboplatin in the GeparSixto [9] and CALGB 40603 [20]
studies have shown an increased pathological complete
response (pCR) rate, although with increased toxicity and
without a significant increase in BCS rate. Ongoing studies
such as NRG-BR003 (NCT02488967) [21] and M14-011
BRIGHTNESS (NCT02032277) [22] will provide additional
data on the effects of platinum agents as neoadjuvant or
adjuvant treatment, respectively, on survival outcomes.
To date, neoadjuvant endocrine therapy has been used
less frequently than chemotherapy. Aromatase inhibitorsd. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Clinical benefits and potential concerns associated with neoadjuvant treatment for early breast cancer
Benefits Potential concerns
Impact on surgery  Downstage tumours to permit breast-conserving
surgery rather than mastectomy [4e6],
improving cosmetic outcomes.
 De-escalate surgical treatment of the axilla [7].
 Provide time for germline mutation test results
(i.e. BRCA1/2) that may influence surgical plan.
 Cancer may progress and become inoperable (a
rare event with appropriate monitoring of
response).
 Reduced window of opportunity for fertility
preservation [8].
 Increasing tumour response may not achieve a
reduction in mastectomy rates, regardless of
downstaging and effectiveness of therapy
regimen [9,10].
 Increased locoregional recurrence rates in
patients who do not undergo surgery after
neoadjuvant treatment [11].
Disease information
and monitoring
 Provide individualised post-treatment prognostic
information (e.g. pathological complete response,
residual cancer burden) for management
decisions.
 Permits clinicians to monitor response to
therapy at an early stage; potentially allowing
time and flexibility to switch therapies if
patients do not respond [12,13].
 Potential loss of staging information.
 Potential for over-treatment, if decision is based
on incomplete information (e.g. size of lesion is
overestimated because of associated ductal
carcinoma in situ seen radiologically).
 Potential for under-treatment if therapy is
stopped or changed mid-course [14].
 Limited evidence base to guide adjuvant radio-
therapy decisions or management of patients
with residual disease.
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women with larger, hormone receptor-rich breast cancers),
usually when systemic chemotherapy is not indicated
either due to tumour biology or patient characteristics
[17,18,23]. This may include node-positive or node-negative
patients [23,24].With appropriate patient selection, the risk
of disease progression is low, although treatment duration
is longer than for NAC [25]. A trial of 182 patients treated
with neoadjuvant letrozole showed a 69.8% BCS rate at 3
months, rising to 83.5% after 2 years of treatment [26].
Llombart-Cussac et al. [27] reported a median time to
maximum response with letrozole of 4.2 months. However,
over a third of responding patients required more than 6
months of treatment. A recent meta-analysis of 20 studies
indicated that neoadjuvant endocrine therapy may be as
effective as NAC, but with lower toxicity [28]. Therefore,
neoadjuvant endocrine treatment should be considered in
selected patients.Initiating Neoadjuvant Treatment
Factors to Consider when Selecting Patients for Neoadjuvant
Therapy
Although there is consensus on the patient subgroups
most likely to benefit from neoadjuvant treatment
[17,18], its utilisation in clinical practice remains highly
variable [29e31]. All early stage breast cancer patients
identified as likely to require adjuvant chemotherapy
should be considered for NAC, as they may potentiallybenefit from treatment before surgery. Factors favouring
NAC in patients with operable breast cancer include:
 high tumour volume-to-breast ratio;
 lymph node-positive disease;
 biological features of primary cancer (high grade, hor-
mone receptor-negative, HER2-positive, TNBC);
 younger age.
The efficacy of neoadjuvant treatment is assessed by
evaluating the clinical and radiological response during and
after therapy, and the pathological response after surgery.
The likelihood of achieving a significant response is pre-
dicted by cancer phenotype; patients with HER2-positive
and TNBC have the highest probability of achieving pCR
after NAC (up to 50.3% for hormone receptor-negative/
HER2-positive patients receiving HER2-targeted therapy,
and 33.6% for TNBC) [32], making them good candidates for
NAC consideration [32,33]. By contrast, pCR rates are lower
for hormone receptor-positive/HER2-negative cancers;
however, patients in this group may still achieve a mean-
ingful clinical and radiological response from NAC, partic-
ularly younger patients with grade 3 cancers and low
hormone receptor levels. Careful selection within these
subgroups is required.
Histological subtype is also important. Invasive lobular
cancers (ILCs) represent 10e15% of breast cancers and are
typically hormone receptor-positive and histological grade
2. NAC is less beneficial in this group: fewer patients are
downstaged to permit successful BCS, re-excision rates after
BCS are higher and the likelihood of pCR is significantly
lower than invasive cancers of no special type (NST) [34].
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rates were observed in ILC than invasive NST [35]. The
number needed-to-treat to achieve significant downstaging
was higher in ILC (11.5 and 15.4 for cT2 and cT3, respec-
tively) than in invasive NST (8.5 and 7.2, respectively) [36].
The greatest likelihood of response is in ILCs with more
aggressive biological features (i.e. grade 3, hormone re-
ceptor-negative/HER2-positive) [35,36]. Lower response
rates have also been reported in mucinous, metaplastic and
apocrine carcinomas [37].
As discussed, DFS and overall survival seem to be
equivalent in studies where identical chemotherapy was
given pre- versus postoperatively [1e3], contradicting the
original hypothesis that early treatment of micro-
metastatic disease would improve survival. Nevertheless,
given the current appreciation of the importance of
intrinsic subtype in almost every aspect of breast cancer
behaviour, it is important to ask whether there may be
specific patients to whom neoadjuvant therapy should be
administered to improve long-term outcomes. A trend for
improved overall survival was noted in the NSABP B-18
study in women aged younger than 50 years treated with
NAC compared with adjuvant chemotherapy, and this
might reflect the increased frequency of hormone
receptor-negative disease in younger patients [6]. A pro-
spective registry study also reported a trend towards
improved DFS in TNBC patients who received NAC,Information to be discussed with the MDT when
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Breast cancer treatment has evolved into a truly multi-
disciplinary endeavour, requiring a team that includes
surgeons, clinical and medical oncologists, radiologists,
pathologists and nurses in patient care. When discussing
neoadjuvant treatment, it is crucial that provisional histo-
logical grade (i.e. derived from the core biopsy specimen),
hormone receptor and HER2 results, and radiological re-
sults are available at the MDT meeting [39]. MDT discus-
sions should include the proposed surgical plan after
treatment, which will be determined by the tumour
response to NAC.
Figure 1 provides a suggestion for the information that
should be available and discussed to aid decision-making by
theMDT. Once a patient has been identified for neoadjuvant
therapy, radiological marker clips should be placed in the
breast, and any positive nodes should also be marked pre-
treatment [40].
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Treatment
Monitoring during Neoadjuvant Treatment
Clinical assessments and imaging are the mainstay when
monitoring treatment response and aid the early identifi-
cation of potential disease progression. Imaging should
include a bilateral mammogram and/or breast ultrasound,
both before and after NAC, and repeated during the treat-
ment course if there are any clinical concerns regarding
progression. For neoadjuvant endocrine therapy, 3-monthly
assessments can be completed. Studies have suggested a
potential correlation between early radiological response
and pCR [42].
Not all patients require magnetic resonance imaging
(MRI) during NAC treatment [18,43,44], but it is the most
accurate and sensitive modality for identifying residual
disease after treatment [18,44,45]. MRI accurately pre-
dicts pathological findings in TNBC, HER2-positive and
hormone receptor-negative tumours [46], with signifi-
cant correlations between MRI and tumour changes dur-
ing NAC [47]. MRI can be helpful for the purposes of
surgical planning [13,44] and is indicated in cases where
there are discrepancies between mammography and
ultrasound, as it may influence subsequent surgical
decision-making.
The full course of NAC should be completed unless there
is evidence of disease progression. Although the concept of
‘response-guided’ therapy is attractive, it is still evolving as
clinical data regarding its effectiveness are as yet incon-
clusive [48]. It is crucial for MDTs to review the small
number of patients who experience cancer progression
during NAC; the appropriate action for most of these pa-
tients is to cease treatment and proceed immediately to
surgery and/or radiotherapy.Surgical Management of Patients after
Neoadjuvant Therapy
Advantages of Breast-conserving Surgery
BCS improves psychosocial and cosmetic outcomes after
breast cancer surgery over mastectomy [49,50]. Hence, a
key benefit of neoadjuvant treatment is enabling BCS for
patients in whom mastectomy would otherwise be indi-
cated. Indeed, studies have shown that NAC increases BCS
rates [2,51], although patients eligible for BCS may still opt
for mastectomy [52]. As cosmetic outcome is influenced by
the volume of tissue excised [53], it is logical to assume that
an NAC-mediated reduction in resection volume will
improve cosmetic outcome, but not all studies have shown
a reduced excised volume at BCS after NAC [54]. When
the tumour lies in a cosmetically sensitive area (i.e. the
upper inner quadrant) it is acceptable to use NAC to reduce
the volume of excised tissue necessary in patients suitable
for BCS.There are circumstances where mastectomy may be
indicated despite a good response to NAC. These include the
presence of widespread malignant microcalcifications
(confirmed histologically to represent ductal carcinoma in
situ), BRCA1/2 gene mutation carriers considering a bilateral
risk reduction, or patient choice.
Previous concerns of increased locoregional recurrence
(LRR) risk following NAC to downstage and permit BCS [55]
have not been borne out. Studies have suggested that BCS
combined with whole breast radiotherapy is no different to
or has a higher survival rate than mastectomy [56e59] with
similar LRR rates. A recent meta-analysis of TNBC suggests
that LRR rates for BCS plus radiotherapy are lower than for
mastectomy [60]. Furthermore, a meta-analysis of eight
studies has shown that as long as surgery remained a
component of the treatment pathway, there was no in-
crease in LRR rates after BCS [11]. The concerns surrounding
operative complications after NAC are similarly unfounded,
as the rate is low, even for patients undergoing immediate
breast reconstruction [11,61].
Patterns of tumour response may influence surgical
planning. There are two general patterns of response
after NAC: concentric shrinkage or a scattergun/honeycomb
response (Figure 2), where the residual carcinoma presents
as multiple, scattered foci over an ill-defined tumour bed
[62,63]. This latter pattern of response is particularly
problematic when planning surgical procedures, as
obtaining clear margins is more difficult [63].
Recent improvements of systemic therapy efficacy in
specific subtypes such as hormone receptor-negative/
HER2-positive disease, where pCR rates exceed 60%, raise
the question of whether surgery could be omitted in pa-
tients who achieve a radiological complete response after
NAC [64,65]. At present, this remains a research question
and is being explored in the UK and Europe by the NOSTRA
andMICRA [66] trials, respectively, although surgery should
not be omitted without evidence from such clinical trials
[64,65].
Defining the Surgical Margin
Local margin guidelines accepted for primary BCS should
also be adopted for BCS post-NAC. The most appropriate
marginwidth after NAC has not been defined separately, but
even for patients with adverse biology, the available evi-
dence does not suggest a need to increase surgical margin
width [67,68].
Managing the Axilla: Timing Sentinel Lymph Node Biopsy
Local guidelines on management of the axilla should be
followed as per MDT discussion before initiating NAC; the
final decision on sentinel lymph node biopsy (SLNB) should
be taken after full clinical and radiological axillary assess-
ment after neoadjuvant treatment. In the UK, post-NAC
SLNB is now accepted practice in patients with pre-
treatment negative nodes (ultrasound scan with or
without fine needle aspiration/core biopsy), although this is
not uniformly applied even though lymph node staging
Scattergun/Honeycomb
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Fig 2. Patterns of response following neoadjuvant treatment. Hae-
matoxylin and eosin (H&E) stained section of tumour bed with fibrosis
and elastosis indicating response to neoadjuvant chemotherapy. (A)
Low power view; scanty scattered islands of residual invasive carci-
noma are present (blue arrows), box represents view of (B). (B) High
power view, showing oedema (red arrows), fibrosis (yellow arrows)
and residual small islands of invasive carcinoma (blue arrows).
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node status at the outset [69], and SLNB accurately stages
the axilla in patients who are clinically node negative at
diagnosis [7]. The management of pre-NAC node-positivepatients is more controversial, with many patients con-
demned to axillary clearance. There is now increasing evi-
dence that this represents over-treatment, particularly in
patients with HER2-positive and TNBC tumours, since they
achieve a high nodal pCR rate, as shown by post-NAC SLNB
[69]. Axillary clearance carried out on patients with nodal
pCR may be regarded, at least in retrospect, as a failure
of current decision-making algorithms, and efforts must
continue to be applied to reduce the exposure of patients to
the morbidity of an axillary clearance. Crucially, this de-
pends on the accuracy of post-NAC SLNB. Based on results
from the Z-1071 study, post-NAC SLNB should retrievemore
than two nodes to reduce the false negative rate to 9.1%; the
accuracy of SLNB after NAC is directly related to the number
of nodes retrieved [70]. If adequate numbers cannot be
retrieved, then axillary lymph node dissection should be
considered [69]. This practice is being prospectively evalu-
ated in the UK by the ROSCO trial (EudraCT 2013-004307-
39) [71]. A targeted axillary dissection using a combination
of removing the clipped node and SLNB provides a high
degree of accuracy in assessing the post-NAC axilla [72].
Implementing these recommendations can reduce false
negative rates to as low as 2.0% [40].Patient Management after Neoadjuvant
Treatment and Surgery
The Basis for Radiotherapy Planning and Management
It is generally recommended that patients who have BCS
undergo radiotherapy [41], but there is more uncertainty
regarding post-mastectomy chest wall radiotherapy. In the
absence of clear guidelines, there is concern about whether
to base radiotherapy decisions on the tumour parameters
before or after NAC. Most evidence guiding radiotherapy
originates from adjuvant clinical trials, but this evidence
can also support decision-making with neoadjuvant treat-
ment. The recent EBCTCG meta-analysis of post-
mastectomy patients showed that chest wall radiotherapy
reduced both the recurrence and mortality rates of node-
positive patients even after systemic adjuvant chemo-
therapy [73], suggesting that chest wall radiotherapy is
appropriate in post-NAC patients who remain node posi-
tive. For patients who achieve pCR after NAC, the results
from the NSABP B-18 and B-27 studies showed very low
rates of LRR post-mastectomy in the absence of radio-
therapy [74], suggesting that omission of radiotherapy may
be possible in this subset. However, these data arise from a
relatively small number of patients, and the omission of
chest wall and regional nodal radiotherapy after pCR re-
mains an area of controversy that is being addressed by the
ongoing NSABP B-51/RTOG 1304 study [75].
If patients have not achieved pCR after NAC, other pa-
rameters may assist radiotherapy decisions, such as tumour
size, skin (e.g. T4 stage) or nodal involvement. In the latter
case, supraclavicular fossa (SCF) radiotherapy should be
considered if four or more axillary lymph nodes are
involved after NAC, as would be the case in patients who
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nodes after NAC, the decision around SCF radiotherapy is
less clear, as these patients would not receive SCF radio-
therapy in the adjuvant setting. However, in the neo-
adjuvant setting, there is a concern that the patient may
have had a heavier lymph node burden at baseline, despite
the downstaging achieved with NAC. If there is histopath-
ological evidence of scarring and treatment response in
other nodes, it is reasonable to consider SCF radiotherapy
on this basis, although there is no direct evidence from
clinical trials that confirms or refutes this at present.
Axillary radiotherapy should be considered if the pa-
tient is sentinel node positive and has not had axillary
clearance [41].
At the moment, there is no specific evidence relating to
the use of a tumour bed boost following neoadjuvant
radiotherapy. Therefore, patients should be treated per
standard protocols for the adjuvant setting. While the
relative benefits of a boost seem to apply broadly, absolute
benefits are greater in women 50 years of age and younger
[76]. Recent consensus statements issued by the Royal
College of Radiologists in the UK recommend a boost for all
patients who have undergone BCS and are younger than 50
years old, with consideration in those over 50 years with
higher risk pathological features (especially grade 3 and/or
extensive intraductal component) [77].
It is clear that balancing potential risks of over-treatment
with the risks of under-treatment (e.g. increased LRR rates
and decreased survival) in the absence of definitive data is not
straightforward [78]. In practice, mostMDTs continue to adopt
a conservative approach in line with the guidelines issued by
the American National Comprehensive Cancer Network,
which state that the indications for radiotherapy should beTable 2
Residual cancer burden definitions and estimated relapse-free survival
Residual cancer
burden risk class
Definition Cut-off
RCB-0 No traces of residual disease
(complete pathologic response)
RCB ¼ 0
RCB-I Minimal residual disease 1.36
RCB-II Moderate residual disease >1.36
RCB-III Extensive residual disease >3.28
HER2, human epidermal growth factor 2; HR, hormone receptor; RCB,
* Data from Symmans et al. [87] for patients treated with paclitaxel folbased on the maximum/worst stage from the pre- or post-
treatment pathological stage and tumour characteristics [19].
Pathological Complete Response as a Measure of Efficacy of
Neoadjuvant Chemotherapy
Using pCR as a prognostic marker of long-term outcome
for the individual patient is well established [79]; achieving
pCR is associated with improved survival outcomes [32,33].
The probability of achieving pCR depends on cancer sub-
type and is seenmost frequently in TNBC and HER2-positive
tumours. The association between pCR and survival out-
comes is not as evident in slowly proliferating, hormone
receptor-positive [80], luminal A cancers [81]. The predic-
tive validity of pCR is therefore variable and dependent on
the tumour biology.
pCR is also recognised by regulatory authorities such as
the European Medicines Agency and the Food and Drug
Administration as a standard efficacy endpoint to evaluate
drugs given as NAC in early breast cancer clinical trials,
pending confirmatory results from large adjuvant studies
[32,82,83]. These bodies have provided standardised pCR
definitions in their guidance [82,83]. However, definitions
used in practice vary, which has implications when evalu-
ating the outcomes of clinical trials [84].
In addition to pCR, the residual cancer burden provides
another method to assess NAC response by incorporating bi-
dimensional measurements of the residual tumour, histo-
logical assessment of the tumour cellularity and nodal disease
burden (number of nodes involved and size of largest
metastasis) to estimate the volume of residual disease [85].
Patients are placed in three risk groups, which are associated
with distant relapse-free survival [63,85,86] (Table 2).rates
Estimated percentage of relapse-free survival of patients
treated with T/FAC, % (95% confidence interval)*
5-year 10-year
Overall: 92 (86, 96)
TNBC: 94 (84, 98);
HRþ/HER2e: 88 (72, 95);
HER2þ: 94 (80, 99)
Overall: 86 (78, 91)
TNBC: 86 (73, 93);
HRþ/HER2e: 83 (63, 93);
HER2þ: 88 (72, 96)
Overall: 94 (88, 97)
TNBC: 89 (73, 96);
HRþ/HER2e: 100;
HER2þ: 89 (61, 97)
Overall: 85 (75, 91)
TNBC: 81 (63, 93);
HRþ/HER2e: 97 (81, 100);
HER2þ: 63 (35, 82)
Overall: 80 (76, 84)
TNBC: 62 (50, 72);
HRþ/HER2e: 87 (82, 90);
HER2þ: 62 (42, 76)
Overall: 68 (62, 73)
TNBC: 55 (43, 66)
HRþ/HER2e: 74 (67, 80);
HER2þ: 44 (26, 61)
Overall: 58 (50, 65)
TNBC: 26 (14, 41);
HRþ/HER2e: 70 (60, 77);
HER2þ: 47 (23, 68)
Overall: 46 (37, 54)
TNBC: 23 (12, 37);
HRþ/HER2e: 52 (40, 63);
HER2þ: 47 (23, 68)
residual cancer burden; TNBC, triple negative breast cancer.
lowed by fluorouracil, doxorubicin and cyclophosphamide (T/FAC).
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not Achieve a Pathological Complete Response
Recent advances in adjuvant chemotherapy may offer
additional options for patients who have not achieved pCR.
The CREATE-X study randomised patients with HER2-
negative cancer and residual disease post-NAC to receive
eight cycles of capecitabine versus placebo and reported
improved 5-year DFS and overall survival in favour of cape-
citabine [88]. A similar approach in the ongoing KATHERINE
study (NCT01772472) [89] evaluates trastuzumab emtansine
as adjuvant therapy in HER2-positive patients without pCR
following NAC. Trials such as PENELOPE-B (NCT01864746)
[90] are evaluating the cyclin-dependent kinase 4/6 inhibi-
tor, palbociclib, in hormone receptor-positive patients.
We anticipate that clinical trials will increasingly recruit
from the subgroup of patients without pCR. It is therefore
important for the MDT to be aware of national study port-
folios, as these trials may only be open at a subset of sites,
necessitating referral to the nearest centre. Recruitment to
these studies may offer patients with a high predicted
subsequent event rate access to therapies beyond standard
practice.
Communicating Treatment Response to Patients
It is essential to communicate to patients that achieving
pCR is not the only positive outcome measure of NAC, as
downstaging from mastectomy to BCS, irrespective of pCR,
is itself a positive outcome.
Data on patient perception and psychological morbidity
in relation to NAC response are limited. One study’s patients
with locally advanced breast cancer reported increased
levels of anxiety and depression in patients whose
tumour size did not decrease by more than 50% after
treatment [91].
As pCR is less frequent and less strongly associated with
recurrence in hormone receptor-positive/HER2-negative
cancers, the failure to achieve pCR here does not inevi-
tably reflect a poor outcome. It is important for patients to
understand that adjuvant endocrine therapy will be offered
to reduce the risk of disease recurrence, so setting patients’
expectations of treatment goals is crucial.Conclusion
When evaluating outcomes such as DFS and overall
survival, NAC is at least equivalent to adjuvant treatment.
However, NAC may bring other potential benefits. There-
fore, we strongly urge the MDT to consider whether an
early breast cancer patient may benefit from treatment
before surgery. Clinical trials for new drugs and novel
combinations increasingly exploit neoadjuvant use and
will be key to improving treatment of patient subgroups.
Particularly, the opportunity for individualised molecular
assessment during neoadjuvant therapy will further
enhance scientific understanding of breast cancer biology
and behaviour.Although current guidelines have now specified recom-
mendations for neoadjuvant treatment in early stage breast
cancer [17,19,41], consensus needs to be reached to ensure
that all patients who could potentially benefit are discussed
by the MDT before any surgical intervention, in order to
provide the optimum care for each early breast cancer
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